{"id":145420,"date":"2026-07-09T12:43:20","date_gmt":"2026-07-09T07:13:20","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=145420"},"modified":"2026-07-09T12:43:21","modified_gmt":"2026-07-09T07:13:21","slug":"piramal-pharma-share-price-usfda-eir-sellersville","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/","title":{"rendered":"Piramal Pharma Share Price Jumps 2.5 Percent on 9 July 2026 as USFDA Issues Establishment Inspection Report for Sellersville Facility"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>USFDA issues Establishment Inspection Report (EIR) for Piramal Pharma&#8217;s Sellersville, USA facility. Piramal Pharma share price at Rs 172.25, up 2.47%. Day range Rs 166.45 to Rs 175.95.<\/em><\/p>\n<p>The <a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-ltd-share-price-today\">Piramal Pharma<\/a> share price jumped 2.47 percent on 9 July 2026 after the US FDA issued an Establishment Inspection Report, or EIR, for the company&#8217;s manufacturing facility located at Sellersville in the United States. The Piramal Pharma share price touched an intraday high of Rs 175.95 on the news, with trading volumes running well above the stock&#8217;s typical average.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=piramal-pharma-usfda-eir-sellersville-facility\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_the_USFDA_Establishment_Inspection_Report_Means_for_the_Piramal_Pharma_Share_Price\" title=\"What the USFDA Establishment Inspection Report Means for the Piramal Pharma Share Price\">What the USFDA Establishment Inspection Report Means for the Piramal Pharma Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Piramal_Pharma_Share_Price_Snapshot\" title=\"Piramal Pharma Share Price Snapshot\">Piramal Pharma Share Price Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Background_The_May_2026_Form-483_at_Sellersville\" title=\"Background: The May 2026 Form-483 at Sellersville\">Background: The May 2026 Form-483 at Sellersville<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Why_This_Matters_for_Piramal_Pharmas_CDMO_Business_and_Share_Price_Outlook\" title=\"Why This Matters for Piramal Pharma&#8217;s CDMO Business and Share Price Outlook\">Why This Matters for Piramal Pharma&#8217;s CDMO Business and Share Price Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_Investors_Should_Watch_Next_for_the_Piramal_Pharma_Share_Price\" title=\"What Investors Should Watch Next for the Piramal Pharma Share Price\">What Investors Should Watch Next for the Piramal Pharma Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Frequently_Asked_Questions_FAQs\" title=\"Frequently Asked Questions FAQs\">Frequently Asked Questions FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Why_did_the_Piramal_Pharma_share_price_rise_today\" title=\"Why did the Piramal Pharma share price rise today?\">Why did the Piramal Pharma share price rise today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_is_an_Establishment_Inspection_Report_and_why_does_it_matter\" title=\"What is an Establishment Inspection Report and why does it matter?\">What is an Establishment Inspection Report and why does it matter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_was_the_background_to_the_Sellersville_facility_inspection\" title=\"What was the background to the Sellersville facility inspection?\">What was the background to the Sellersville facility inspection?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_was_the_Piramal_Pharma_share_price_today\" title=\"What was the Piramal Pharma share price today?\">What was the Piramal Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#What_does_the_Sellersville_facility_manufacture\" title=\"What does the Sellersville facility manufacture?\">What does the Sellersville facility manufacture?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-usfda-eir-sellersville\/#Does_receiving_an_EIR_mean_the_facility_had_no_issues_at_all\" title=\"Does receiving an EIR mean the facility had no issues at all?\">Does receiving an EIR mean the facility had no issues at all?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_the_USFDA_Establishment_Inspection_Report_Means_for_the_Piramal_Pharma_Share_Price\"><\/span><strong>What the USFDA Establishment Inspection Report Means for the Piramal Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>An Establishment Inspection Report is the formal document the US FDA issues once it has completed its full review of a manufacturing facility inspection, including its assessment of any corrective actions the company has submitted in response to earlier findings. Its issuance effectively closes out the inspection cycle for that specific facility, giving both the company and the market clarity that the regulator considers the matter resolved, at least for the current inspection round, allowing operations at the site to continue without an unresolved compliance overhang, a key reason behind today&#8217;s Piramal Pharma share price gain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Snapshot\"><\/span><strong>Piramal Pharma Share Price Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises today&#8217;s Piramal Pharma share price action.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Current price<\/td>\n<td>Rs 172.25, up 2.47 percent<\/td>\n<\/tr>\n<tr>\n<td>Intraday high<\/td>\n<td>Rs 175.95<\/td>\n<\/tr>\n<tr>\n<td>Intraday low<\/td>\n<td>Rs 166.45<\/td>\n<\/tr>\n<tr>\n<td>Trading volume<\/td>\n<td>290,935 shares vs 202,141 five day average (+43.93%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get Pharma and CDMO Sector Views from SEBI Registered Investment Advisors<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Background_The_May_2026_Form-483_at_Sellersville\"><\/span><strong>Background: The May 2026 Form-483 at Sellersville<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Today&#8217;s Piramal Pharma share price move is best understood against the backdrop of events from earlier this year. The Sellersville, USA facility underwent a Good Manufacturing Practices inspection by the US FDA from 4 May to 8 May 2026. At the conclusion of that inspection, the agency issued a Form-483 containing three observations, and importantly, the company confirmed at the time that none of the observations were related to data integrity, a distinction that matters significantly to regulators and investors alike, since data integrity concerns are typically viewed as more serious red flags than procedural or documentation-related observations. Inspectors had recommended a Voluntary Action Indicated, or VAI, classification during the closing meeting, which generally signals that the observations are of a nature the company can resolve through its own corrective actions without more severe regulatory escalation.<\/p>\n<p>Following that inspection, Piramal Pharma stated it was preparing a detailed response to the observations for submission to the US FDA within the required timelines. Today&#8217;s issuance of the Establishment Inspection Report represents the culmination of that process, with the regulator having reviewed the company&#8217;s response and formally closed the inspection.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_This_Matters_for_Piramal_Pharmas_CDMO_Business_and_Share_Price_Outlook\"><\/span><strong>Why This Matters for Piramal Pharma&#8217;s CDMO Business and Share Price Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Piramal Pharma operates a global network of manufacturing and development facilities as part of its contract development and manufacturing organisation, or CDMO, business, serving pharmaceutical clients worldwide, a business mix directly relevant to how investors are reading today&#8217;s Piramal Pharma share price move. For a CDMO, maintaining clean regulatory standing across its manufacturing network is critical, since clients evaluating contract manufacturing partners place significant weight on a facility&#8217;s compliance track record with major regulators like the US FDA. A successfully closed inspection, even one that involved some initial observations, reinforces confidence among existing and prospective clients that the facility can be relied upon for consistent, compliant production, which can support the company&#8217;s ability to win and retain manufacturing contracts at the Sellersville site going forward.<\/p>\n<p>Piramal Pharma has faced a mix of inspection outcomes across its broader facility network in recent periods, with some sites achieving No Action Indicated status with zero observations, while others, including Sellersville, have had to work through Form-483 observations before reaching closure. The successful resolution at Sellersville adds to the company&#8217;s overall track record of engaging constructively with the regulator to resolve findings within the VAI framework, avoiding more serious classifications that could restrict a facility&#8217;s ability to manufacture and export products to the US market, a positive backdrop for the Piramal Pharma share price.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_Next_for_the_Piramal_Pharma_Share_Price\"><\/span><strong>What Investors Should Watch Next for the Piramal Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors tracking the Piramal Pharma share price should watch for any further regulatory updates across the company&#8217;s other global manufacturing sites, along with commentary in upcoming quarterly results on how the Sellersville facility&#8217;s operations and order book have been affected, if at all, by the inspection cycle now concluded. Given that CDMO revenue visibility depends heavily on maintaining strong regulatory standing across a company&#8217;s facility network, continued clean inspection outcomes at other sites would further support investor confidence in the Piramal Pharma share price and the company&#8217;s broader manufacturing quality systems.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stock-market-app\/id1585303974\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.app\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Piramal Pharma share price and pharma sector regulatory updates live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The USFDA&#8217;s issuance of the Establishment Inspection Report for Piramal Pharma&#8217;s Sellersville facility marks a positive resolution to the Form-483 observations raised during the May 2026 inspection, and the market has responded with a 2.47 percent rally in the Piramal Pharma share price. Investors tracking the Piramal Pharma share price should view this as a constructive regulatory milestone that removes an overhang on the facility, while continuing to monitor the company&#8217;s broader CDMO facility network for further compliance updates.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span><strong>Frequently Asked Questions FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_the_Piramal_Pharma_share_price_rise_today\"><\/span><strong>Why did the Piramal Pharma share price rise today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma share price rose 2.47 percent on 9 July 2026 after the US FDA issued an Establishment Inspection Report, or EIR, for the company&#8217;s manufacturing facility located at Sellersville in the United States.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_an_Establishment_Inspection_Report_and_why_does_it_matter\"><\/span><strong>What is an Establishment Inspection Report and why does it matter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> An Establishment Inspection Report is the US FDA&#8217;s formal closing document for a manufacturing facility inspection, and its issuance signals that the regulator has completed its review and is satisfied with the facility&#8217;s response to any earlier findings, effectively closing out the inspection cycle for that site.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_background_to_the_Sellersville_facility_inspection\"><\/span><strong>What was the background to the Sellersville facility inspection?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The US FDA had conducted a Good Manufacturing Practices inspection at the Sellersville facility from 4 May to 8 May 2026, which concluded with a Form-483 carrying three observations, none related to data integrity, with inspectors recommending a Voluntary Action Indicated, or VAI, classification at the time.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Piramal_Pharma_share_price_today\"><\/span><strong>What was the Piramal Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Piramal Pharma was quoting at Rs 172.25, up Rs 4.15 or 2.47 percent, having touched an intraday high of Rs 175.95 and a low of Rs 166.45, with trading volumes running well above the stock&#8217;s five day average.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Sellersville_facility_manufacture\"><\/span><strong>What does the Sellersville facility manufacture?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Sellersville, USA facility is one of Piramal Pharma&#8217;s global manufacturing sites and forms part of the company&#8217;s contract development and manufacturing organisation, or CDMO, network, which produces a range of pharmaceutical products and services for global clients.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_receiving_an_EIR_mean_the_facility_had_no_issues_at_all\"><\/span><strong>Does receiving an EIR mean the facility had no issues at all?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Not necessarily. In this case, the facility had earlier received a Form-483 with three observations that were not related to data integrity, and the EIR issuance indicates the FDA has since reviewed the company&#8217;s corrective response and formally closed the inspection, which is generally viewed as a positive regulatory outcome even when some initial observations were raised.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why did the Piramal Pharma share price rise today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Piramal Pharma share price rose 2.47 percent on 9 July 2026 after the US FDA issued an Establishment Inspection Report, or EIR, for the company's manufacturing facility located at Sellersville in the United States.\"}},{\"@type\":\"Question\",\"name\":\"What is an Establishment Inspection Report and why does it matter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"An Establishment Inspection Report is the US FDA's formal closing document for a manufacturing facility inspection, and its issuance signals that the regulator has completed its review and is satisfied with the facility's response to any earlier findings, effectively closing out the inspection cycle for that site.\"}},{\"@type\":\"Question\",\"name\":\"What was the background to the Sellersville facility inspection?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The US FDA had conducted a Good Manufacturing Practices inspection at the Sellersville facility from 4 May to 8 May 2026, which concluded with a Form-483 carrying three observations, none related to data integrity, with inspectors recommending a Voluntary Action Indicated, or VAI, classification at the time.\"}},{\"@type\":\"Question\",\"name\":\"What was the Piramal Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Piramal Pharma was quoting at Rs 172.25, up Rs 4.15 or 2.47 percent, having touched an intraday high of Rs 175.95 and a low of Rs 166.45, with trading volumes running well above the stock's five day average.\"}},{\"@type\":\"Question\",\"name\":\"What does the Sellersville facility manufacture?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Sellersville, USA facility is one of Piramal Pharma's global manufacturing sites and forms part of the company's contract development and manufacturing organisation, or CDMO, network, which produces a range of pharmaceutical products and services for global clients.\"}},{\"@type\":\"Question\",\"name\":\"Does receiving an EIR mean the facility had no issues at all?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Not necessarily. In this case, the facility had earlier received a Form-483 with three observations that were not related to data integrity, and the EIR issuance indicates the FDA has since reviewed the company's corrective response and formally closed the inspection, which is generally viewed as a positive regulatory outcome even when some initial observations were raised.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma share price rose 2.47 percent on 9 July 2026 after the USFDA issued an Establishment Inspection Report for its Sellersville, USA manufacturing facility.<\/p>\n","protected":false},"author":26,"featured_media":145434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-145420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783581204:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_focus_keyword":["Piramal Pharma Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Piramal Pharma Share Price Jumps 2.5% on USFDA EIR Clearance"],"rank_math_description":["Piramal Pharma share price rose 2.47 percent on 9 July 2026 after the USFDA issued an Establishment Inspection Report for its Sellersville, USA manufacturing facility."],"_thumbnail_id":["145434"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["24831"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Piramal-Pharma-Share-Price-Jumps-2.5-Percent-on-9-July-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/145420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=145420"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/145420\/revisions"}],"predecessor-version":[{"id":145435,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/145420\/revisions\/145435"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/145434"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=145420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=145420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=145420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}